Join us at the Alumni Reception
Join us at our Alumni Reception on Sunday, September 29th, from 9-11 p.m., at the Yardbird Table & Bar. All former and current residents, fellows, staff, spouses, companions and friends are welcome.
Upcoming Events
Date |
Time |
Author |
Title |
Abstract |
Location |
| December 7th | 12:30 p.m. - 12:45 p.m. EST |
Paolo Caimi, MD and J. Joseph Melenhorst, PhD
|
Baseline immune and proteomic profiling predicts response and resistance to CD19 CAR Tcell therapy in B-cell non-Hodgkin lymphoma: Insights from a decentralized manufacturing clinical trial | abs25-4222 | OCCC - Tangerine Ballroom F3-4 |
| December 7th | 4:45 p.m. - 5 p.m. EST | Shahzad Raza, MD | Efficacy and safety of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma and extramedullary disease: Updated Phase 2 results from the redirectt-1 study with extended follow-up | abs25-8381 | OCCC - West Hall E1 |
| December 7th | 5:30 p.m. - 5:45 p.m. EST |
Abhay Singh, MD, MPH, Akriti Jain, MD and Hetty Carraway, MD
|
Ivosidenib leads to durable responses in IDH1 mutated clonal cytopenias of undetermined significance: A phase II decentralized clinical trial | abs25-9445 | OCCC - W312 |
| December 7th | 6 p.m. - 8 p.m. EST |
Aaron Gerds, MD, MS
|
Using a medically trained LLM-based end-to-end system in automating patient eligibility screening across a health system for A phase 3 study evaluating the safety of givinostat in patients with polycythemia vera | abs25-8815 | OCCC - West Halls B3-B4 |
| December 8th | 10:30 a.m. - 10:45 a.m. EST |
Dana Angelini, MD
|
Black lives advocating for clot knowledge (B.L.A.C.K) national blood clot alliance church bus tour: A community-based blood clot education and awareness campaign | abs25-11331 | Hyatt - Regency Ballroom OPQ |
The cancer treatment landscape is changing, with new approvals coming fast and furious.
Catch up on what some of our physicians had to talk about at ASCO.
Cleveland Clinic helped lead the conversation in blood cancer research this year at ASH. Check out these key study outcomes from our providers that were featured at the conference.
Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in.
Renowned for its expertise, the Cleveland Clinic Cancer Institute provides multidisciplinary cancer care, offers access to cutting-edge clinical trials, and support programs across Northeast Ohio, Florida, Abu Dhabi and coming soon in London, aiming to help cancer patients improve their quality of life and achieve long-term survival.
Cleveland Clinic provides world-class care to patients with cancer. Our nationally ranked cancer program is at the forefront of new and emerging clinical, translational and basic cancer research.
Dedicated to Advancing Cancer Care and Research
As a multidisciplinary, collaborative practice, we are committed to working with you to provide the best care for your patients, and to educate the next generation of medical professionals at all our facilities worldwide.
Notable Abstracts at ASH 2025
Join Cleveland Clinic at the American Society of Hematology (ASH) Annual Meeting to explore the latest breakthroughs in hematology research. With more than 140 pieces of research being presented, Cleveland Clinic continues to lead innovation in the field. Here are the top 5 must-see abstracts, featuring key insights on B-cell non-Hodgkin’s lymphoma, high-risk multiple myeloma, and polycythemia.
Save the Date
All former and current residents, fellows, staff, friends and spouses / companions of Cleveland Clinic are welcome to attend our Alumni Reception on Sunday, September 29th, from 9-11 p.m., at the Yardbird Table & Bar.
| Date | Time | Title | Abstract/Poster# | Location |
|
May 31st
|
9 AM - 12 PM
|
Risk of Intracranial Hemorrhage with DOACs vs LMWH in patients with cancer-associated thrombosis and brain metastases | 2034 | Hall A |
|
May 31st
|
9 AM - 12 PM
|
A Phase II Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma: ECOG-ACRIN EA2187 | 4115 | Hall A |
|
May 31st
|
1:30-4:30 PM
|
Comparable efficacy and safety of taletrectinib for advanced ROS1+ non–small cell lung cancer across pivotal studies and between races and world regions. | 8643 | Hall A |
|
May 31st
|
1:15 PM
|
Phase 3 randomized trial (KEYNOTE-630) of adjuvant pembrolizumab (pembro) versus placebo (pbo) for high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) following surgery and radiation (RT) | 6000 | S100a |
|
June 3rd
|
12:09 PM
|
Safety and efficacy data from Nexicart-2, the first US trial of CAR-T in R/R light chain (AL) amyloidosis, Nxc-201 | 7508 | S100bc |
Roy Miller, MD
Roy Miller, MD
Our team is involved in many posters and presentations.
Renowned for its expertise, the Cleveland Clinic Cancer Institute provides multidisciplinary cancer care, offers access to cutting-edge clinical trials, and support programs across Northeast Ohio, Florida, London, and Abu Dhabi aiming to help cancer patients improve their quality of life and achieve long-term survival.
Hear what our physicians had to say about their research featured at ASH.
Hairy Cell Leukemia Complicated by Severe COVID-19: A Case Study
Novel three-drug regimen used to manage life-threatening developments
Consult QD
A site for physicians and healthcare professionals. Discover the latest cancer research insights, innovations and emerging advances from Cleveland Clinic Cancer Center specialists.
Roy Miler, MD
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore e.
S12: Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et
Dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Risus commodo viverra maecenas accumsan lacus vel facilisis. Lorem ipsum dolor sit amet, consectetur. Tityre, tu patulae recubans sub tegmine fagi dolor. Quae vero auctorem tractata ab fiducia dicuntur. Salutantibus vitae elit libero, a pharetra augue. Quam diu etiam furor iste tuus nos eludet? Quisque placerat facilisis egestas cillum dolore. Contra legem facit qui id facit quod lex prohibet. Praeterea iter est quasdam res quas ex communi. Fabio vel iudice vincam, sunt in culpa qui officia. Ambitioni dedisse scripsisse iudicaretur.
Inmensae subtilitatis, obscuris et malesuada fames. Paullum deliquit, ponderibus modulisque suis ratio utitur. Nihil hic munitissimus habendi senatus locus, nihil horum? Qui ipsorum lingua Celtae, nostra Galli appellantur. Pellentesque habitant morbi tristique senectus et netus. Etiam habebis sem dicantur magna mollis euismod.
Cum ceteris in veneratione tui montes, nascetur mus. Morbi fringilla convallis sapien, id pulvinar odio volutpat. Lorem ipsum dolor sit amet, consectetur adipisici elit, sed eiusmod tempor incidunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation. Quid securi etiam tamquam eu fugiat nulla pariatur.
Cum sociis natoque penatibus et magnis dis parturient. Cras mattis iudicium purus sit amet fermentum. Magna pars studiorum, prodita quaerimus. Curabitur est gravida et libero vitae dictum. Ullamco laboris nisi ut aliquid ex ea commodi consequat.
Roy Miler, MD
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore e.
S12: Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et
Dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Risus commodo viverra maecenas accumsan lacus vel facilisis. Lorem ipsum dolor sit amet, consectetur. Tityre, tu patulae recubans sub tegmine fagi dolor. Quae vero auctorem tractata ab fiducia dicuntur. Salutantibus vitae elit libero, a pharetra augue. Quam diu etiam furor iste tuus nos eludet? Quisque placerat facilisis egestas cillum dolore. Contra legem facit qui id facit quod lex prohibet. Praeterea iter est quasdam res quas ex communi. Fabio vel iudice vincam, sunt in culpa qui officia. Ambitioni dedisse scripsisse iudicaretur.
Inmensae subtilitatis, obscuris et malesuada fames. Paullum deliquit, ponderibus modulisque suis ratio utitur. Nihil hic munitissimus habendi senatus locus, nihil horum? Qui ipsorum lingua Celtae, nostra Galli appellantur. Pellentesque habitant morbi tristique senectus et netus. Etiam habebis sem dicantur magna mollis euismod.
Cum ceteris in veneratione tui montes, nascetur mus. Morbi fringilla convallis sapien, id pulvinar odio volutpat. Lorem ipsum dolor sit amet, consectetur adipisici elit, sed eiusmod tempor incidunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation. Quid securi etiam tamquam eu fugiat nulla pariatur.
Cum sociis natoque penatibus et magnis dis parturient. Cras mattis iudicium purus sit amet fermentum. Magna pars studiorum, prodita quaerimus. Curabitur est gravida et libero vitae dictum. Ullamco laboris nisi ut aliquid ex ea commodi consequat.
Consult QD
A site for physicians and healthcare professionals. Discover the latest cancer research insights, innovations and emerging advances from Cleveland Clinic Cancer Center specialists.
S14 - A: Nullam in enim ullamcorper, efficitur dui a, fermentum erat. Cras in massa eget nisi imperdiet hendrerit vel interdum tellus. Ut pellentesque neque ipsum, quis fringilla nisl volutpat vel. Cras et luctus ipsum, quis blandit ligula. Morbi elementum tincidunt nibh eu lobortis. Ut consectetur ut libero sed sagittis.
S14 - A: Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et
Dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Risus commodo viverra maecenas accumsan lacus vel facilisis. Lorem ipsum dolor sit amet, consectetur adipiscing elit.
AI Screening Platform Accelerates Trial Recruitment in Polycythemia Vera
IDH1 Inhibitor Found Safe and Effective in Rare Precursor to Blood Malignancies
Palliative Care Addresses an Unmet Need in Sickle Cell Disease
Dual Bispecifics May Redefine Management of Extramedullary Myeloma
Novel Community Campaign Increases Venous Thromboembolism Awareness
National Blood Clot Alliance collaborates with faith-based organizations on first-of-its-kind church bus tour.
Researchers Identify Predictors of Response to CAR T-Cell Therapy in B-Cell Non-Hodgkin’s Lymphoma
Distinct baseline immune profiles can predict response and resistance to different types of CAR-T cells.
Cleveland Clinic Children’s Hospital for Rehabilitation
Address:
18101 Lorain Ave
Cleveland, OH 44111
Hours:
Open 24 hours
Phone:
(216) 476-7000
Emergency room:
Open 24 hours
Cleveland Clinic Children’s Hospital for Rehabilitation
Address:
18101 Lorain Ave
Cleveland, OH 44111
Hours:
Open 24 hours
Phone:
(216) 476-7000
Emergency room:
Open 24 hours
Cleveland Clinic Children’s Hospital for Rehabilitation
Address:
18101 Lorain Ave
Cleveland, OH 44111
Hours:
Open 24 hours
Phone:
(216) 476-7000
Emergency room:
Open 24 hours
Thanks for Connecting at ASH
Subscribe to the Cancer Advances eNewsletter to get the latest Cleveland Clinic cancer-related research and insights.
Thank you for signing up.